INBRX-101 is a fusion protein commercialized by Inhibrx, with a leading Phase II program in Emphysema. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of INBRX-101s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for INBRX-101 is expected to reach an annual total of $419 mn by 2040 globally based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
INBRX-101 Overview
SAR-447537 (INBRX-101) is under the development for the treatment of alpha-1 antitrypsin deficiency, graft versus host disease (GVHD) and emphysema. The therapeutic candidate comprises of alpha-1 antitrypsin (AAT)-Fc fusion proteins and developed based on VAST-mAb (validated ablation of self-tolerance) platform.
Inhibrx Overview
Inhibrx is a biotechnology company that discovers and develops biologic therapeutics for the treatment of cancer and infectious diseases. It is investigating INBRX-109, an engineered tetravalent sdAb-based therapeutic candidate to treat cancer by activating DR5 (death receptor 5). The company is also evaluating the INBRX-106 program against advanced or metastatic solid tumors; and INBRX-105 therapeutic candidate targeting patients with programmed death-ligand 1 (PD-L1) expressing tumors. It utilizes its proprietary sdAb (single-domain antibody) platform to develop biotherapeutics that interface with the biology of each target antigen by focusing on immune activation and mediating enhanced signaling. Inhibrx is headquartered in La Jolla, California, the US.
The company reported revenues of (US Dollars) US$1.8 million for the fiscal year ended December 2023 (FY2023), a decrease of 17.9% over FY2022. The operating loss of the company was US$219.2 million in FY2023, compared to an operating loss of US$129.1 million in FY2022. The net loss of the company was US$241.4 million in FY2023, compared to a net loss of US$145.2 million in FY2022.
For a complete picture of INBRX-101s valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
